November 11, 2004

20/20 and Celgene Entered the Second Phase of Development of a Monitoring Tool for 

Determining In Vivo Activity of JNK Inhibitors 20/20 GeneSystems, Inc. 

and Celgene initiateda Phase II project whose goalis to develop a monitoring tool for determining 

in vivo activity of JNK inhibitors. 

This tool would use hair as a surrogate tissue to determine the systemic pharmacodynamic effects 

of JNK inhibitors and tailor the dose of drug for each patient.  

For more information on this project contact Jonathan Cohen

Back to News page